Company news

Amplia Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Quarterly Activities/Appendix 4C Cash Flow Report

October 27, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

October 27, 2026

Amplia Receives R&D Tax Rebate Totalling $4.78 Million

October 21, 2026

Amplia Therapeutics Provides Clinical Trial Updates

October 21, 2026

Response to ASX Price Query

October 15, 2026

Response to ASX Price Query

October 15, 2026

Amplia Presents at CG Drug and Device Conference 2026

October 12, 2026

Amplia Presents at E&P Healthcare Conference 2026

September 16, 2026

Amplia and ANZGOG Finalise Protocol for Ovarian Cancer Trial

September 14, 2026

Notification regarding unquoted securities - ATX

September 9, 2026

Results of Annual General Meeting

August 27, 2026

CEO Managing Director Presentation to Annual General Meeting

August 27, 2026

Bioshares Biotech Summit Presentation

August 5, 2026

Amplia signs Collaboration and Supply Agreement with Lilly

August 3, 2026

Scientific Paper Detailing Preclinical Studies of Narmafotinib in Pancreatic Cancer Now Online

July 31, 2026

Scientific Paper Studies of narmafotinib - Pancreatic Cancer

July 30, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

July 28, 2026

Notice of Annual General Meeting/Proxy Form

July 27, 2026

Amplia Announces Publication of New FAK Inhibitor Patent Application

July 9, 2026

Amplia Announces Appointment of Brett Carter to Board

July 7, 2026

Amplia Announces Changes to Board’s Leadership Roles

July 6, 2026

Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic Cancer

June 22, 2026

Preliminary Final Report and Annual Report YE 31 March 2026

May 28, 2026

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

May 19, 2026

Amplia Launches First Stage of Pivotal Narmafotinib Trial

May 18, 2026

Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study

May 8, 2026

Amplia and ANZGOG announce Ovarian Cancer Study

May 7, 2026

Accent Trial Mature Data Presented at International Conference

April 22, 2026

Amplia Therapeutics Halts Recruitment in AMPLICITY Trial

April 6, 2026

Amplia Therapeutics Reports Four Additional Complete Responses and Improved Overall Survival Data in Accent Pancreatic Cancer Trial

March 23, 2026

Amplia Reports Improved Responses & Survival in ACCENT trial

March 22, 2026

Trading Halt

March 19, 2026

Pause in Trading

March 18, 2026

Amplia Therapeutics to Present at the Life Sciences Investor Forum on March 12th

March 11, 2026

Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models

March 9, 2026

Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial

February 11, 2026

Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025

January 30, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 29, 2026

NARMAFOTINIB Large-Scale Manufactre Complete

January 22, 2026

ACCENT data presented at 2026 asco gastrointestinal cancer symposium

January 12, 2026

Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium

December 23, 2025

Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors

December 19, 2025

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

December 12, 2025

Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th

December 8, 2025

Key Narmafotinib Patent Granted in the U.S.

December 3, 2025

Half Yearly Report and Accounts

November 27, 2025

Positive Response from US FDA to Amplia's Type D Meeting

November 19, 2025

Amplia Receives R&D Tax Rebate Totalling $3.77 Million

October 27, 2025

First patient dosed in new pancreatic cancer trial

September 3, 2025

Amplia Share Purchase Plan Raises $2.65 Million

August 25, 2025

Older news releases →

Decks

The 5 newest of 31 decks. Every deck is listed under its year.